Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio. The associated price target remains the same with $10.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight the potential of Gossamer Bio’s seralutinib as a promising therapy. The literature review conducted in 2025 has reinforced confidence in the drug’s durability and its relevance to right-heart functions. The open-label extension following the Phase 2 trial demonstrated sustained improvements in hemodynamics and functional gains over seventy-two weeks, which includes a reduction in pulmonary vascular resistance and an increase in six-minute walk distance among patients continuing the treatment. These findings suggest a disease-modifying effect rather than just temporary vasodilatory benefits.
Additionally, the review highlighted the drug’s potential for long-term value in treating high-need pulmonary conditions. The literature also supports the combination of seralutinib with other therapies, enhancing its positioning as a foundational treatment in multi-mechanism regimens. Upcoming catalysts, such as the Phase 3 PROSERA trial results expected in February 2026, are anticipated to further validate seralutinib’s efficacy and safety, supporting the Buy rating and the $10 price target for Gossamer Bio’s stock.
In another report released on August 6, Leerink Partners also reiterated a Buy rating on the stock with a $6.00 price target.